Recruiting Lymphoma Studies in Iowa City
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that ...
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab...
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD19 and C...
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compli...
Study of LYL314 in Aggressive Large B-Cell Lymphoma
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 ...
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
The primary purpose of the study is to assess the pharmacokinetics (PK) profile of pembrolizumab following subcutaneous (SC) injection of pembrolizumab coformulated with hyaluronidase, and to evaluate...
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose...
MB-105 in Patients With CD5 Positive T-cell Lymphoma
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon tw...
About Lymphoma Clinical Trials in Iowa City
Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.
There are currently 8 lymphoma clinical trials recruiting participants in Iowa City, IA. These studies are seeking a combined 2,261 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Janssen Research & Development, LLC and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lymphoma Clinical Trials in Iowa City — FAQ
Are there lymphoma clinical trials in Iowa City?
Yes, there are 8 lymphoma clinical trials currently recruiting in Iowa City, IA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Iowa City?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Iowa City research site will contact you about next steps.
Are clinical trials in Iowa City free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Iowa City studies also compensate for your time and travel.
What lymphoma treatments are being tested?
The 8 active trials in Iowa City are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.
Data updated March 2, 2026 from ClinicalTrials.gov